Quantumzyme Corp. (OTCQB: QTZM), a leader in computational enzyme engineering and digital biocatalysis, announced the expansion of its AI-powered enzyme design platform to target additional high-volume Active Pharmaceutical Ingredients (APIs) beyond ibuprofen. This strategic move aims to advance green pharmaceutical manufacturing by reducing hazardous waste, toxic solvent use, and carbon emissions at scale.
Building on its validated enzymatic process for green ibuprofen synthesis, the company is leveraging its enzyme families, machine learning predictive models, and in silico design workflows to develop sustainable pathways for other APIs with significant environmental impact. The expanded R&D pipeline includes chiral intermediates such as phenylephrine and related compounds accessible via ketoreductases, which are widely used in the generics sector.
The global API market is projected to exceed $300 billion by 2030, with generic drugs representing the majority of production volume. Much of this manufacturing currently relies on legacy chemistries that generate heavy waste streams and high solvent and carbon intensity. Quantumzyme's biocatalysis-first approach offers a sustainable alternative that delivers reduced chemical waste and solvent usage, lower carbon footprint, elimination of toxic reagents, and improved cost and yield efficiency.
Quantumzyme's enzyme engineering platform integrates advanced AI-driven computational modeling, in silico directed evolution, mechanistic simulation, and high-throughput validation to deliver optimized biocatalysts that replace traditional energy-intensive chemical reaction steps. This expansion highlights the scalability of the company's digital biology architecture and its ability to rapidly adapt and redeploy enzyme systems across diverse synthesis targets.
By extending its enzyme engineering platform beyond ibuprofen, Quantumzyme is advancing greener chemistry, supporting supply chain resiliency, and moving closer to a future where enzyme-driven production becomes the industry standard for high-volume APIs. The company's platform also supports domestic API manufacturing and aligns with U.S. supply chain resilience and sustainability goals.
For more information, visit www.quantumzymecorp.com and the company's profile at www.otcmarkets.com/stock/QTZM.
